Introduction {#s1}
============

Breast cancer remains the most common cancer in women worldwide and rated second in cancer related mortality ([@B33]). Breast cancer treatment strategies and prognosis are guided by classification into molecular subtypes as there are: Luminal A, Luminal B, her-2-neu positive and triple negative/basal-like tumours. Surgery remains the primary treatment in most cases and entails the complete removal of the primary tumour in the breast and a surgical staging of the axilla. Adjuvant treatment is dictated by stage of disease, type of surgery and the molecular subtype of the primary tumour ([@B18]).

Our understanding of carcinogenesis was driven by the observation that a tumour consists of cell groups (clones) with molecular and phenotypic differences. This phenomenon is known as tumour heterogeneity and is caused by differences in susceptibility for genetic mutations, epigenetic alterations and differences in tumour microenvironment ([@B5]; [@B16]; [@B30]). Tumour heterogeneity constitutes a challenge for cancer research and treatment. The immediate implication of intra tumour heterogeneity is that a specific clone of tumour cells as a result of its aggressive biological behaviour might be responsible for the ultimate outcome of the patient whilst it remains unrecognized by the tumour profiling techniques available at present. Inter tumour heterogeneity on the other hand implicates a change in characteristics between the primary tumour and its metastases. This potentially involves changes in drug sensitivity/resistance ([@B30]).

Whilst developing more advanced tumour profiling techniques and clinically useful biomarkers to target therapy one wonders whether it would not be more effective in case of lymph node positive breast cancer (LNPBC) to direct adjuvant therapy towards the nature of the ALNM rather than that of the primary breast tumour removed by surgery. In order to explore this hypothesis we searched the literature for data on inter tumour heterogeneity in LNPBC.

Materials and Methods {#s2}
=====================

2.1. Types of studies {#s2a}
---------------------

Breast cancer studies reporting on the expression of ER or PR or her-2-neu in primary breast tumour and its metastases (synchronous and/or metachronous) were included. Both prospective and retrospective studies were included.

A comprehensive search was performed in Pubmed, articles published from 2000 until 2015, selected by 3 readers (EVD, GVDP, EDJ). The following MeSH headings were used: HUMAN and BREAST NEOPLASMS and RECEPTORS and ErbB-2. Only full text articles written in English were selected ([Fig. 1](#g001){ref-type="fig"}).

![--- Search strategy](FVVinObGyn-7-251-g001){#g001}

2.2. Subjects {#s2b}
-------------

All women included in this analysis had a histological diagnosis of primary breast cancer and ipsilateral, synchronous ALNM. If studied, pathological information on possible asynchronous, distant metastasis was processed as well. No inclusion restrictions were retained regarding age, menopausal stage or type of treatment.

2.3. Types of outcome measurements {#s2c}
----------------------------------

Hormone receptor analysis in the studies included was performed by immunohistochemistry, in which positive interpretation requires at least 1% of tumour cells showing positive nuclear staining of any intensity. Her-2-neu status was tested with two possible methods: immunohistochemistry and/or fluorescence in situ hybridization. Tumour heterogeneity was interpreted as a difference in expression of biomarkers.

Results {#s3}
=======

A summary of articles reporting on breast cancer and the concordance regarding ER, PR and her-2-neu expression between the primary breast tumour and synchronous or metachronous metastases is shown in Tables [I](#T1){ref-type="table"} and [II](#T2){ref-type="table"}. The majority of studies are retrospective, consists of small numbers of women and in most studies a central pathology review was performed. In general there is a shift in the ER/PR/her-2-neu profile in 10-20 % of synchronous ALNM and 20-40% of metachronous metastases. Both losses and/or gain of receptor expression were noticed. In metachronous metastases loss of receptor expression was more pronounced. Loss of ER, PR and/or her-2-neu expression occurred in 25%, 33% and 8% of cases respectively in these combined series, whilst gain of receptor expression was seen in 8%, 8% and 12% of cases respectively ([@B28]; [@B20]; [@B23]; [@B24]; [@B21]).

###### 

--- ER, PR, and her-2-neu expression profiles: concordance (%) between the primary breast tumour and synchronous LNM.

  --------------------------------------------------------------------------------------------------------
  **Author**   **Study structure**                **Number of patients**   **Biomarker**           
  ------------ ---------------------------------- ------------------------ --------------- ------- -------
  [@B14]       Retrospective\                     425                      93%             84%     97%
               pT1-2 N1M0                                                                          

  [@B11]       Retrospective\                     90                       96.6%           96.6%   96.1%
               LNPBC\                                                                              
               (\> 10 positive LN, M0)                                                             

  [@B22]       Retrospective\                     148                      \-              \-      95.3%
               LNPBC (M0)                                                                          

  [@B2]        Retrospective\                     385                      71.6%           76.5%   91.1%
               High grade LNPBC (M0)                                                               

  [@B1]        Retrospective\                     108                      96.5%           97.6%   95.5%
               T1-3 N1M0                                                                           

  [@B19]       Prospective\                       165                      83%             97%     97%
               LNP(macro)BC                                                                        

  [@B23]       Retrospective                      53                       96%             \-      100%

  [@B9]        Retrospective\                     47                       \-              \-      100%
               M+                                                                                  

  [@B4]        Prospective\                       119                      97.4%           96.6%   96.6%
               LNPBC                                                                               

  [@B7]        Fine needle aspiration cytology\   38                       94.7%           86.8%   92%
               LNPBC                                                                               

  [@B3]        Retrospective\                     60                       \-              \-      91.6%
               LNPBC                                                                               
  --------------------------------------------------------------------------------------------------------

###### 

--- ER, PR, and her-2-neu expression profiles: concordance (%) between the primary breast tumour and metachronous metastasis.

  **Author**   **Study structure**   **Number of patients**   **Biomarker**           
  ------------ --------------------- ------------------------ --------------- ------- -------
  [@B21]       Retrospective         120                      83.6%           58.3%   82.5%
  [@B20]       Retrospective         233                      89.7%           70%     94.8%
  [@B24]       Retrospective         1010                     66.4%           68%     84.3%
  [@B23]       Prospective           119                      88%             \-      91%
  [@B28]       Prospective           25                       60%             60%     92%

Discussion {#s4}
==========

In this review of the literature we studied the reported changes in biological profile between the primary breast tumour and its metastases at the level of ER, PR and her-2-neu expression as biomarkers which to date are used in daily clinical practice to guide systemic adjuvant therapy in breast cancer. In general there was no significant change seen in biomarker profile between the primary breast tumour and its synchronous ALNM ([@B9]; D' Andrea et al., 2007; [@B14]; [@B1]; [@B4]; [@B19]; [@B23]; [@B22]). The results of [@B2] are in contrast to the concordance rates mentioned earlier as they found a disparate breast/node status for at least one biomarker (ER of PR) in almost 50% of cases, resulting in ALNM with worse prognostic profile illustrated by shifts to ER negativity and her-2-neu positivity. A study population consisting of highgrade primary breast tumours only is a possible explanation for these aberrant results. Systematic evaluation of these biomarkers in ALNM therefore is not recommended. On the contrary inter tumour heterogeneity between primary tumours of the breast and distant metachronous metastases are responsible for a significant change of tumour features (Table II). In the event of metachronous disease, the biomarker status of this new locus should be reassessed to optimize adjuvant therapy in order to improve patient outcome. Detection of loss of function in this new tumour locus reflected in a change/loss of an immunohistochemical biomarker should avoid ineffective therapy based on the biomarker signature of the primary breast tumour and direct therapy into different treatment strategies of proven efficacy.

Removal of involved lymph nodes is no longer believed to improve prognosis in breast cancer although their presence remains an important negative prognostic factor for relapse and death in breast cancer ([@B17]; [@B13]). It remains uncertain which role the tumour cells colonizing synchronous ALNM play in the mechanism of dissemination to organs at distance. Do tumour cells disseminate to distant organs via synchronous ALNM or does lymphogenic and hematogenic spread operate through different mechanisms? Tumour cells designed to metastasize hematogenously seem to be biologically different from the tumour cells found in ALNM ([@B31]).

[@B15] revisited the 'seed and soil' hypothesis describing the process of metastasis and explaining why specific tumour types (the 'seed') spread to specific organs (the 'soil'). It is clear now that throughout the process of tumour progression cells acquire genetic variations and instability, which determines whether their phenotype predisposes to dissemination. In the event of dissemination, the locus of metastasis is not random and not only depending on anatomical barriers. The microenvironment of each organ is different. Different cell surface receptors and variable growth factors are responsible for a tumour cell specific and host specific response. This revisited 'seed and soil' hypothesis explains why tumour cells emerging in synchronous ALNM have a phenotype different from those in metachronous metastases. The reason for high concordance in biomarker expression between the primary breast tumour and the synchronous ALNM is less clear: the migration of tumour cells to the axilla is either based on a different mechanism than the one that dictates dissemination to distant loci. Therefore other biomarkers remaining unrevealed to date may differentiate between tumour cells present in the primary breast tumour and the synchronous ALNM.

However to date no studies have been conducted examining differences in outcome of breast cancer therapy comparing systemic therapy directed against the biomarker expression in synchronous ALNM versus the biomarker expression in primary breast tumour.

To interfere with disease progression targets other than tumour cells in synchronous ALNM could be explored: the xenograft model to study tumour behaviour in the laboratory, molecular imaging with biomarkers to locate and bio-type metastatic tumour and the concept of circulating tumour cells to improve therapy in an early stage of disease.

An in vivo mouse-hosted patient derived xenograft (PDX) is likely to reflect tumour biology better than in vitro cell lines derived from tumours. The study of tumour behaviour and tumour heterogeneity should be more accurate in PDX. It is a promising model for basic research in oncology and phase I interventional studies with new compounds ([@B32]). For instance tumour grafting in the mammary glands of mice gives rise to metastasis with patterns similar to those observed in the original breast cancer patients ([@B12]). Likewise, aurora kinase inhibitor, a cell-cycle regulator, was tested in triple negative breast cancer xenografts to study its potential as a new anticancer drug ([@B27]).

Non-invasive assessment of receptor status by molecular imaging via PET or SPECT whether or not combined with CT or MRI may become a way of identifying therapeutic anchors in the individual patient. Developing isotopic marked target molecules against ER, PR, her-2-neu or other clinically useful molecular targets (radiopharmaceuticals) could reveal receptor status of tumour sites in particular tumour deposits not amenable for biopsy. Biomarker specific targeting agents are labelled with positron or gamma-emitting radionuclides, optical dyes or paramagnetic contrast molecules for PET, SPECT and MRI respectively ([@B8]; [@B29]).

The phenomenon of circulating tumour cells (CTCs) was described as early as in the 1800's ([@B26]).

[@B10] tested the hypothesis that levels of CTCs can predict survival in metastatic breast cancer and concluded that the number of CTCs before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer. Detection, quantification and characterization of CTCs open new perspectives on cancer dissemination and treatment. In the current staging of breast cancer the finding of CTCs is referred to as a stage cM0 (i+). Studies on CTCs and breast cancer are in phase 3, offering major perspectives for both biological and clinical research on the metastatic process ([@B6]). Hypothetically CTCs could be a marker of 'active' disease and a precursor of metastatic disease. Biomarker expression in CTCs was described by [@B25]. They were able to detect CTCs in 31% of 54 patients with early stage breast cancer and found a 20% discordance in her-2-neu expression between primary breast tumour and CTCs.

In conclusion, tumour heterogeneity constitutes a challenge for cancer research and therapy. We reviewed the data on the ER, PR and her-2-neu expression both in the primary breast tumour and its synchronous ALNM and metachronous metastases as the most used biomarkers in breast cancer in daily clinical practice to date. A high concordance between primary breast tumour and synchronous ALNM was seen. Therefore determination of ER, PR, her-2-neu on synchronous ALNM to tune systemic therapy and therefore outcome is not contributing. Since tumour heterogeneity between the primary breast tumour and metachronous metastasis is ascertained, distant metastasis should be biopsied and their biomarker profile direct therapeutic planning. The process of dissemination of tumour cells and implications for cancer treatment however remains unclear. To date we know that ALNM in breast cancer are important for prognosis, their removal does not impact on survival and their biological profile does not predict the biological characteristics of metachronous metastasis. Both the exploration of new biomarkers in ALNM and the biological profile of CTCs therefore could be the next step in our understanding of inter tumour heterogeneity and its therapeutic consequences.
